Biodexa Pharmaceuticals Reports 12-Month Survival in Glioblastoma Patients
Biodexa Pharmaceuticals (Nasdaq: BDRX) has provided survival updates from its clinical study of MTX110 in patients with recurrent glioblastoma (“rGBM”). Currently, no standard of care is established for rGBM.
The company’s MAGIC-G1 trial is an open-label, dose escalation study designed to assess the feasibility and safety of intermittent infusions of MTX110 administered by convection enhanced delivery via implanted refillable pump and catheter.
Commenting on the study in 2023, Dr Dmitry Zamoryakhin, MD, MBA, CSO of Biodexa, said, “We are pleased with the progress of the study and collaboration with our investigational sites. No observed dose limiting toxicities is an encouraging signal that justifies continuation of the development of MTX-110 for treatment of this devastating disease with high unmet medical need.”
GBM is the most common and devastating primary malignant brain tumor in adults. The current standard of care, which includes a multidisciplinary approach including surgery and radiation or chemotherapy, still results in almost all patients experiencing tumor progression with nearly universal mortality.
MTX110 is delivered directly into and around the patient’s tumor via a catheter system to bypass the blood-brain barrier, exposing the tumor to very high drug concentrations while simultaneously minimizing systemic drug levels and the potential for toxicity and other side effects.
MTX110 is a water-soluble form of panobinostat free base, which has demonstrated high potency against diffuse intrinsic pontine glioma (DIPG) tumor cells in in vitro and in vivo models.
About Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs. The Company’s lead development programmes include tolimidone, under development as a novel agent for the treatment of type 1 diabetes and MTX110, which is being studied in aggressive rare/orphan brain cancer indications, and
Tolimidone is an orally delivered, potent and selective inhibitor of lyn kinase. Lyn is a member of the Src family of protein tyrosine kinases, which is mainly expressed in hematopoietic cells, in neural tissues, liver, and adipose tissue. Tolimidone demonstrates glycemic control via insulin sensitization in animal models of diabetes and has the potential to become a first in class blood glucose modulating agent.
MTX110 is a solubilised formulation of the histone deacetylase (HDAC) inhibitor, panobinostat. This proprietary formulation enables delivery of the product via convection-enhanced delivery (CED) at chemotherapeutic doses directly to the site of the tumour, by-passing the blood-brain barrier and potentially avoiding systemic toxicity.
Biodexa is supported by three proprietary drug delivery technologies focused on improving the bio-delivery and bio-distribution of medicines. Biodexa’s headquarters and R&D facility is in Cardiff, UK. For more information visit www.biodexapharma.com.
